Edwards Lifesciences EW Rest of World — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edwards Lifesciences's rest of world — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edwards Lifesciences's rest of world — net sales?
- Edwards Lifesciences (EW) reported rest of world — net sales of $177.8M in Q1 2026.
- How has Edwards Lifesciences's rest of world — net sales changed year-over-year?
- Edwards Lifesciences's rest of world — net sales increased by 18.4% year-over-year, from $150.2M to $177.8M.
- What is the long-term trend for Edwards Lifesciences's rest of world — net sales?
- Over 4 years (2021 to 2025), Edwards Lifesciences's rest of world — net sales has grown at a 5.2% compound annual growth rate (CAGR), from $533.2M to $652.3M.
- What does rest of world — net sales mean?
- This metric represents the total revenue generated from product sales and services within geographic regions outside of the company's primary established markets, such as the US, Europe, and Japan. It serves as a key indicator of the company's ability to penetrate emerging markets and expand its global footprint in the structural heart disease sector. Growth in this segment reflects successful international commercialization strategies and adoption of medical technologies in developing healthcare systems.